Zhang et al. were able to show that the up-regulation of muscle MSTN in patients with CKD depends on an IL6/Jak/Stat3/CAAT/enhancer-binding protein δ pathway, which is a potential target for therapy [17,60]. Here, IL6 is linked to chronic kidney disease.